Sélectionnez votre langue
Sélectionnez votre langue
As part of its research, Ambiotis announces promising results on a model of IBD and intestinal irritation to evaluate pro-resolving compounds. The model presents a specific metabolipidomic signature that contains immunoresolvent molecules.
This model will thus represent a tool of choice to test compounds that act on intestinal permeability and inflammation and that aim to restore a good intestinal balance thanks to the mobilization of resolutive pathways.
Ambiotis together with Gattefossé, a major expert in plant extraction and lipochemistry and a leading provider of cosmetic ingredients are both proud to announce the acceptation of a shared abstract to the next International Investigative Dermatology meeting (IID 2018).
The two companies will have the opportunity to expose the results of a fruitful collaboration aiming at investigating inflammation resolution pathways in skin explants.
Ambiotis will attend the two following events :
- Cosmetic 360 - October 18-19, 2017 - Paris, France
- 15th International Conference Bioactive lipids - October 22-25, 2017 - Puerto Vallarta, Mexico